[go: up one dir, main page]

BRPI0517647A - combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina - Google Patents

combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina

Info

Publication number
BRPI0517647A
BRPI0517647A BRPI0517647-6A BRPI0517647A BRPI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A BR PI0517647 A BRPI0517647 A BR PI0517647A
Authority
BR
Brazil
Prior art keywords
combinations
alpha
receptor agonists
nicotinically
acetylcholine receptor
Prior art date
Application number
BRPI0517647-6A
Other languages
English (en)
Inventor
Hans O Kalkman
Joachim Nozulak
Annick Vassout
Konstanze Hurth
Dominik Feuerbach
Conrad Gentsch
Graeme Bilbe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0517647A publication Critical patent/BRPI0517647A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMBINAçõES DE AGONISTAS DO RECEPTOR NICOTìNICO ALFA 7 DE ACETILCOLINA. A presente invenção refere-se a combinações que compreendem pelo menos um agonista do receptor nicotínico alfa 7 de acetilcolina e pelo menos um composto selecionado a partir do grupo que consiste em (a) antipsicóticos convencionais (b) antipsicóticos atípicos (c) intensificadores de memória e/ou atenção, cognição (d) e para uso destas combinações no tratamento de distúrbios psiquiátricos.
BRPI0517647-6A 2004-11-05 2005-11-03 combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina BRPI0517647A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424564A GB0424564D0 (en) 2004-11-05 2004-11-05 Organic compounds
PCT/EP2005/011787 WO2006048294A1 (en) 2004-11-05 2005-11-03 Combinations of nicotinic acetylcholine alpha 7 receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0517647A true BRPI0517647A (pt) 2008-10-14

Family

ID=33523294

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517647-6A BRPI0517647A (pt) 2004-11-05 2005-11-03 combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina

Country Status (12)

Country Link
US (2) US20080306081A1 (pt)
EP (3) EP1809285A1 (pt)
JP (3) JP2008518896A (pt)
KR (2) KR20130024974A (pt)
CN (1) CN101039670A (pt)
AU (1) AU2005300691A1 (pt)
BR (1) BRPI0517647A (pt)
CA (1) CA2582436C (pt)
GB (1) GB0424564D0 (pt)
MX (1) MX2007005428A (pt)
RU (1) RU2007120690A (pt)
WO (1) WO2006048294A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
MX2007011436A (es) * 2005-03-18 2007-10-12 Abbott Lab Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CN102014896A (zh) * 2008-02-29 2011-04-13 生物实验萨纽斯药物有限公司 包含西坦和肉毒碱的药物组合物及其制备方法
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2012015749A1 (en) * 2010-07-26 2012-02-02 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
BR112013023813A2 (pt) * 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
EP4251158A1 (en) * 2020-11-25 2023-10-04 Vanda Pharmaceuticals Inc. Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB261309A (en) 1926-07-23 1926-11-18 Oswald Pfeiffer Improvements in collapsible grids
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US3310553A (en) * 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
MXPA04000779A (es) * 2001-08-24 2004-04-20 Pharmacia & Up John Company 7-aza[2.2.1]bicicloheptanos sustituidos con arilo para el tratamiento de enfermedades.
US6919359B2 (en) * 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
EP1542999A1 (en) * 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
PL375533A1 (en) 2002-08-14 2005-11-28 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
WO2004039321A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease
CN1735441A (zh) * 2002-12-11 2006-02-15 法玛西亚普强责任有限公司 治疗注意缺陷多动症的组合
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
CN101946537B (zh) 2008-08-27 2013-01-30 中兴通讯股份有限公司 一种下行信号的分扇区处理方法及基站
US10066977B2 (en) 2009-01-26 2018-09-04 Canon U.S. Life Sciences, Inc. Microfluidic flow monitoring

Also Published As

Publication number Publication date
EP1809285A1 (en) 2007-07-25
US20100125063A1 (en) 2010-05-20
CN101039670A (zh) 2007-09-19
EP2135609A1 (en) 2009-12-23
KR20070073881A (ko) 2007-07-10
JP2008518896A (ja) 2008-06-05
US20080306081A1 (en) 2008-12-11
CA2582436A1 (en) 2006-05-11
WO2006048294A1 (en) 2006-05-11
CA2582436C (en) 2016-10-04
KR101302898B1 (ko) 2013-09-06
RU2007120690A (ru) 2008-12-10
JP2014196328A (ja) 2014-10-16
GB0424564D0 (en) 2004-12-08
KR20130024974A (ko) 2013-03-08
EP2332537A1 (en) 2011-06-15
MX2007005428A (es) 2007-05-18
JP2012255039A (ja) 2012-12-27
AU2005300691A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0517647A (pt) combinações de agonistas do receptor nicotìnico alfa 7 de acetilcolina
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
CL2012002521A1 (es) Composicion farmaceutica que comprende un inhibidor de dpp iv seleccionado de un grupo definido, un primer diluyente, un segundo diluyente: manitol, un segundo diluyente: almidon pregelatinizado, un aglutinante y un lubricante; util en el tratamiento de diabetes. (divisional de la sol. 1260-07).
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
CR9690A (es) 3-acilaminobenzanilidas insecticidas
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
ATE478069T1 (de) 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
BRPI0509687A (pt) seleção e aquisição de sistema para um dispositivo sem fio
MY142044A (en) Endoparasiticidal compositions for topical application
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
BRPI0606081A (pt) método e sistema para impor restrições sobre sessões

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]